Signaling pathway resistance may stem from disrupted IFN-γ signaling in tumor cells, or the dysregulation of oncogenic signaling pathways (WNT–β-catenin, CDK4/6, MAPK cascades). This evidence concerns the gene IFNG and neoplasm.